Acousia Completes Patient Enrollment for Cisplatin Ototoxicity Prevention Study
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
A new study has identified how electrical charges in the inner ear trigger TMPRSS3-related hearing loss—and found that a common drug may help prevent it.
This tool allows doctors to tailor interventions like hearing monitoring or STS use based on each child's specific risk of cisplatin-induced hearing loss.
NIOSH is accepting nominations for the organization's annual Safe-in-Sound Excellence in Hearing Loss Prevention Awards.
NIOSH is now accepting nominations for the 2025 Safe-in-Sound Excellence in Hearing Loss Prevention Award, recognizing efforts in preventing occupational noise-induced hearing loss.
Clinical suggestions that can help people in both roles improve their ability to monitor their music and extend their performing careers.